Drug Digest Editorial Interview Series: Fundamental Constriction Points in Emerging Therapies, High-Titre Vector-Producing Cells: Part 3

Published on: 

Benjamin McLeod, Technical Lead, Virica Biotech, speaks about fundamental constriction points in emerging therapies, high-titre vector-producing cells.


Benjamin serves as Technical Lead with Virica Biotech, a yield-enhancing solution for viral vector and cell therapy production. He is trained in cell biology, biotechnology, and viral vector production. You can find him on LinkedIn, where he regularly posts industry insights and curates papers on process development in CGT.

Register for the full webcast: https://www.pharmtech.com/pt_w/high-titre